Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Efficacy and Safety of a 20 mg/Day Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US, Randomized, Double-blind, 2 Arm, Placebo-controlled, Parallel-group, Fixed Dose, 12-week Study

NCT00464256 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00464256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00464256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Efficacy and Safety of a 20 mg/Day Oral Dose of Rimonabant Versus Placebo as an Aid to Smoking Cessation - a US, Randomized, Double-blind, 2 Arm, Placebo-controlled, Parallel-group, Fixed Dose, 12-week Study
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
November 30, 2004
Enrollment
533 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smoking cessation